Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BeiGene, Ltd. (ONC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ONC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
24 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $330.97
1 Year Target Price $330.97
| 15 | Strong Buy |
| 8 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.89% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 28.04B USD | Price to earnings Ratio - | 1Y Target Price 330.97 |
Price to earnings Ratio - | 1Y Target Price 330.97 | ||
Volume (30-day avg) 24 | Beta 0.29 | 52 Weeks Range 142.00 - 287.88 | Updated Date 06/29/2025 |
52 Weeks Range 142.00 - 287.88 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.4% | Operating Margin (TTM) 0.99% |
Management Effectiveness
Return on Assets (TTM) -3.22% | Return on Equity (TTM) -11.44% |
Valuation
Trailing PE - | Forward PE 135.14 | Enterprise Value 26528455871 | Price to Sales(TTM) 6.72 |
Enterprise Value 26528455871 | Price to Sales(TTM) 6.72 | ||
Enterprise Value to Revenue 6.35 | Enterprise Value to EBITDA - | Shares Outstanding 99369400 | Shares Floating 895677337 |
Shares Outstanding 99369400 | Shares Floating 895677337 | ||
Percent Insiders 17.32 | Percent Institutions 40.1 |
Analyst Ratings
Rating 5 | Target Price 330.97 | Buy 8 | Strong Buy 15 |
Buy 8 | Strong Buy 15 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BeiGene, Ltd.
Company Overview
History and Background
BeiGene, Ltd. was founded in 2010 in Beijing, China. It's a global biotechnology company focused on developing and commercializing innovative cancer medicines. It has rapidly grown from a research-focused organization to a commercial-stage company with a global presence.
Core Business Areas
- Research and Development: Focuses on discovering and developing novel oncology therapeutics.
- Commercialization: Responsible for the marketing and sales of BeiGene's approved drugs in various markets.
- Manufacturing: Manages the production of BeiGene's drug candidates and commercial products.
Leadership and Structure
John V. Oyler serves as the Chairman, Co-Founder, and CEO. The company has a structured executive team overseeing various functional areas like R&D, commercial operations, and finance. They also have a board of directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- BRUKINSA (zanubrutinib): A BTK inhibitor approved for various B-cell malignancies. It competes with Imbruvica (ibrutinib) and Calquence (acalabrutinib). BRUKINSA generated $1.3 Billion in product revenue in 2023, with global market share around 5-10% of the BTK inhibitor market. Competitors are AbbVie, Johnson & Johnson, AstraZeneca.
- Tislelizumab (anti-PD-1 antibody): An anti-PD-1 antibody approved in China and other markets for various solid tumors. Competitors are Keytruda (pembrolizumab) and Opdivo (nivolumab). Competitors are Merck, Bristol Myers Squibb.
- BAF312 (Ociperlimab): An investigational anti-TIGIT antibody. currently in clinical trials. Competitors are Roche and other Anti-TIGIT antibody companies.
Market Dynamics
Industry Overview
The oncology therapeutics market is experiencing substantial growth driven by increasing cancer incidence, advancements in drug development, and the growing adoption of targeted therapies and immunotherapies.
Positioning
BeiGene is positioned as a global biotechnology company focused on developing and commercializing innovative oncology medicines. Its competitive advantages include its strong R&D capabilities, growing commercial infrastructure, and global presence.
Total Addressable Market (TAM)
The global oncology market is expected to reach $376.1 billion by 2030. BeiGene, Ltd. is focused on targeted therapies and immuno-oncology, and positioned to grow into a larger share of this TAM.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Global commercial infrastructure
- Innovative therapies
- Experienced management team
- Strong partnerships
Weaknesses
- Reliance on key products
- High R&D expenses
- Relatively new commercial presence in some markets
- Limited profitability
Opportunities
- Expanding into new markets
- Developing new therapies for unmet medical needs
- Acquiring or partnering with other companies
- Leveraging its manufacturing capabilities
Threats
- Competition from established pharmaceutical companies
- Regulatory challenges
- Pricing pressures
- Clinical trial failures
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- MRK
- BMY
- AZN
- RHHBY
Competitive Landscape
BeiGene, Ltd. faces intense competition from established pharmaceutical companies with larger resources and broader product portfolios. However, BeiGene's innovative therapies and growing global presence position it for continued success.
Growth Trajectory and Initiatives
Historical Growth: BeiGene, Ltd. has experienced rapid revenue growth in recent years, driven by the commercialization of its products and the advancement of its pipeline.
Future Projections: Analysts project continued revenue growth for BeiGene, Ltd. over the next few years, driven by further expansion of its commercial operations and the potential approval of new products. Analyst estimates suggest double-digit revenue growth annually.
Recent Initiatives: Expansion into new markets, strategic collaborations with other pharmaceutical companies, and continued investment in R&D.
Summary
BeiGene, Ltd. is a rapidly growing global biotechnology company with a strong R&D pipeline and a growing commercial presence. While the company is still loss-making, its revenue growth and potential for future profitability are promising. BeiGene needs to carefully manage its expenses and navigate the competitive landscape to achieve its long-term goals. The oncology market is very large and BeiGene is well situated to capitalize on a small portion of this large market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10K, 10Q), Analyst reports, Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available sources. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeiGene, Ltd.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-02-03 | Co-Founder, Executive Chairman & CEO Mr. John V. Oyler | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11000 | Website https://beonemedicines.com |
Full time employees 11000 | Website https://beonemedicines.com | ||
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines Ltd. in May 2025. BeOne Medicines Ltd. was incorporated in 2010 and is based in Basel, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.